CA3219858A1 - Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines - Google Patents

Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines Download PDF

Info

Publication number
CA3219858A1
CA3219858A1 CA3219858A CA3219858A CA3219858A1 CA 3219858 A1 CA3219858 A1 CA 3219858A1 CA 3219858 A CA3219858 A CA 3219858A CA 3219858 A CA3219858 A CA 3219858A CA 3219858 A1 CA3219858 A1 CA 3219858A1
Authority
CA
Canada
Prior art keywords
general formula
compound
cancer
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219858A
Other languages
English (en)
French (fr)
Inventor
Xin Li
Huaide DONG
Guodong Cai
Feng He
Weikang Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of CA3219858A1 publication Critical patent/CA3219858A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3219858A 2021-05-24 2022-05-24 Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines Pending CA3219858A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202110565410 2021-05-24
CN202110565410.0 2021-05-24
CN202110694022 2021-06-22
CN202110694022.2 2021-06-22
CN202110856289.7 2021-07-28
CN202110856289 2021-07-28
CN202210198679.4 2022-03-02
CN202210198679 2022-03-02
PCT/CN2022/094612 WO2022247816A1 (zh) 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CA3219858A1 true CA3219858A1 (en) 2022-12-01

Family

ID=84229501

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219858A Pending CA3219858A1 (en) 2021-05-24 2022-05-24 Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines

Country Status (11)

Country Link
US (1) US20240287094A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349836A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519188A (cg-RX-API-DMAC7.html)
KR (1) KR20240012437A (cg-RX-API-DMAC7.html)
CN (1) CN117177971A (cg-RX-API-DMAC7.html)
AU (1) AU2022280845A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022496A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219858A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013890A (cg-RX-API-DMAC7.html)
TW (1) TWI926045B (cg-RX-API-DMAC7.html)
WO (1) WO2022247816A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501329A (ja) * 2022-12-23 2026-01-14 浙江揚歴医薬技術有限公司 Parp1阻害剤

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
KR20250103773A (ko) * 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
JP2026524090A (ja) 2023-06-08 2026-07-17 上海森▲輝▼医▲葯▼有限公司 ホルムアミド系化合物の製造方法
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parpおよびtank阻害剤としてのキノリノン誘導体
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
WO2020098774A1 (zh) * 2018-11-16 2020-05-22 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
CN116018132A (zh) 2020-06-24 2023-04-25 Itf研究制药有限公司 软明胶胶囊
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501329A (ja) * 2022-12-23 2026-01-14 浙江揚歴医薬技術有限公司 Parp1阻害剤

Also Published As

Publication number Publication date
BR112023022496A2 (pt) 2024-01-16
KR20240012437A (ko) 2024-01-29
TWI926045B (zh) 2026-05-21
CN117177971A (zh) 2023-12-05
EP4349836A4 (en) 2024-10-30
EP4349836A1 (en) 2024-04-10
US20240287094A1 (en) 2024-08-29
WO2022247816A1 (zh) 2022-12-01
AU2022280845A1 (en) 2023-12-14
TW202313630A (zh) 2023-04-01
MX2023013890A (es) 2023-12-11
JP2024519188A (ja) 2024-05-08

Similar Documents

Publication Publication Date Title
AU2022280845A1 (en) Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
EP4563580A1 (en) Fused ring compound, preparation method therefor and medicinal application thereof
EP4361157A1 (en) Fused tetracyclic compound, preparation method therefor and application thereof in medicine
CN113801136B (zh) 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115385937A (zh) 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
CN115368383A (zh) 稠合含氮杂环类化合物、其制备方法及其在医药上的应用
CN117203207A (zh) 桥环类化合物、其制备方法及其在医药上的应用
EP4421076A1 (en) Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
CN115385938A (zh) 苯并嘧啶类化合物、其制备方法及其在医药上的应用
EP4166555A1 (en) Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof
CN113845531B (zh) 吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
EP4253387A1 (en) Fused tricyclic compound, preparation method therefor and application thereof in medicine
CN114907349A (zh) 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
CN119365468A (zh) 稠合二环类化合物、其制备方法及其在医药上的应用
EP4122922A1 (en) Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof
AU2020407600A1 (en) Compounds and probes for imaging huntingtin protein
EP4640684A1 (en) Kras g12d inhibitors and uses thereof
CN113912608A (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
EP4190789A1 (en) Oxa-azaspiro derivative, and preparation method therefor and pharmaceutical use thereof
EA051431B1 (ru) Азотсодержащее гетероциклическое соединение, способ его получения и его применение в качестве ингибитора parp1
CN113135942B (zh) 稠合嘧啶类衍生物、其制备方法及其在医药上的应用
EP4495119A1 (en) Fused heterocyclic compound, and preparation method therefor and medical use thereof
WO2021143821A1 (zh) 稠合杂芳基类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241017

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260430

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260505

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260505